Latest News

MaxCyte to Present at the 2015 Jefferies Immuno-Oncology Summit

 

Gaithersburg, MD, April 15, 2015  – MaxCyte® Inc., the pioneer in cell therapies using scalable, high performance cell transfection systems, today announces that Chief Executive Officer, Doug Doerfler, is to present at the at the 2015 Jefferies Immuno-Oncology Summit in Boston.

 

Mr. Doerfler will present at 9:50am EDT to attending investors. During his presentation Dr. Doerfler will discuss MaxCyte’s expertise in the discovery, development, manufacture, and delivery of innovative cell therapies utilizing best in class cell modification technologies.

 

In particular, Mr. Doerfler will focus on the key advantages offered by CARMA, MaxCyte’s next generation mRNA CAR therapy platform. The Company believes that this technology has the potential to dramatically streamline the current development and manufacturing processes associated with CAR; reducing time, cost and complexity.

 

About MaxCyte

MaxCyte is a world leader in the discovery, development, manufacture, and delivery of innovative cell therapies utilizing best in class cell modification technologies.

MaxCyte has developed a next-generation technology–flow electroporation–for the rapid engineering of human cells as therapeutics, enabling the development of safer, more effective and lower cost cell-based therapies for a broad range of applications with blockbuster commercial potential. The company currently has clinical, pre-clinical-partnered, and proprietary products under development and is presently involved in more than a dozen trials.

The MaxCyte GT® Flow Transfection System is a universal platform for the rapid, automated loading of CAR-modified mRNA into peripheral blood cells, which avoids the time and cost-intensive cell expansion process. The loading of fresh patient cells with CAR mRNA harnesses immune cells for targeted killing of tumors. This anti-tumor activity is not dependent on the patient’s immune system and is independent of cell surface concentration of the tumor antigen.

The Company also markets a portfolio of products and services that include the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System. These platforms are used in drug discovery research and screening and protein production environments by 9 of the top 10 pharma companies worldwide as well as the top three in Japan. MaxCyte products enable the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.

For more information visit /

###

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo